[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100616834":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":47,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"The Netherlands Cancer Institute","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Intra-operative Sonazoid injection",null,[12],"Drug: Sonazoid",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Sonazoid","Intradermal injection of the ultrasound contrast agent Sonazoid.",[9],[20],{"name":21,"affiliation":5,"role":22},"Quirijn Tummers","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Marijn Hiep","CONTACT","+31205121751","ma.hiep@nki.nl",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Netherlands Cancer Institute","RECRUITING","Amsterdam","North Holland","1066 CX","Netherlands",{"type":38,"coordinates":39},"Point",[40,41],4.88969,52.37403,{"lat":41,"lon":40},[44],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48],{"name":49,"class":50},"GE Healthcare","INDUSTRY","100616834",false,"NCT07310758","Contrast-enhanced Ultrasound for Sentinel Node Detection","Contrast-enhanced Ultrasound for Sentinel Node Detection in Patients With Melanoma, Breast Cancer or Head & Neck Cancer","Inclusion Criteria:\n\n* Aged 18 years or older\n* Patient has been diagnosed with cancer in the skin (melanoma), breast or head \\& neck (including melanoma of head and neck area)\n* In case of a melanoma: it should be located in the limbs or head and neck area\n* Scheduled for a surgical SN procedure at the NKI-AvL\n* Patient provides written informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products\n* Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease","ALL","18 Years",{"count":60,"type":61},91,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE2","PHASE3","This is a prospective single-center interventional non-inferiority study where subjects are participating for one day for patients 18 years or older with melanoma, breast cancer or head \\& neck cancer (including melanoma of head and neck area) and scheduled for a surgical SN procedure in the NKI-AvL without any contra-indication for Sonazoid contrast agent, such as an allergy to eggs or egg products. The primary objective is to assess the sensitivity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid). Secondary objectives are the specificity of CEUS for intra-operative SN localization, the time required to localize the SNs using CEUS and intraoperative usability of the CEUS-system. The primary endpoint is the sensitivity of the CEUS SN localization method. The conventional gamma probe will be used as ground truth comparison.",[68,69,70],"Melanoma","Breast Cancer","Head & Neck Cancer",[72],"contrast-enhanced ultrasound","2025-12-16",{"date":75,"type":76},"2025-12-30","ACTUAL",{"date":78,"type":76},"2025-09-18",{"date":80,"type":61},"2026-09-18",{"name":5,"class":6},1]